XBI - SPDR S&P Biotech ETF
| Previous Close | 93.28 |
| Open | 93.95 |
| Bid | 94.31 x 800 |
| Ask | 94.32 x 2200 |
| Day's Range | 93.59 - 94.51 |
| 52 Week Range | 64.38 - 94.95 |
| Volume | 2,320,121 |
| Avg. Volume | 4,981,680 |
| Net Assets | 4.25B |
| NAV | 93.19 |
| PE Ratio (TTM) | N/A |
| Yield | 0.02% |
| YTD Daily Total Return | 29.38% |
| Beta (3Y Monthly) | 1.57 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2006-01-31 |
- Zacks
Is Trade Scaring You? ETF Strategies for 2019 Holiday Season
It is less likely that Santa alone will drive Wall Street this season as trade tensions persist. Overall, these ETF investing trends should stay strong.
- Zacks
A Guide to Biotech ETF Investing
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
- Zacks
Biotech ETF (XBI) Hits a New 52-Week High
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
- Zacks
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Zacks
Why Biotech ETFs Surged in Monday's Trading Session
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.
- ETF Trends
Biotech ETFs Pop After Novartis Acquires Medicines Co.
Biotechnology ETFs led the charge on Monday after Novartis AG (NYSE: NVG) agreed to buy Medicine Co. (NasdaqGS: MDCO) as the Swiss multinational pharmaceutical company moves to expand its treatment for ...
- Investopedia
Stocks Are Getting Bought, but Not Overbought Yet
To teach a kid a lesson, keep it simple. Tell him in plain language what he did wrong, and give a simple punishment that fits the offense. Right? Throw the ball in the house and break something, you clean it up and work to replace it.
- Investopedia
Big Buying in Software and Biotech Stocks Is Bullish
While the market will eventually need to vent and pull back, buyers remain in control, with buying in software and biotech.
- Zacks
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
- Zacks
Follow Morgan Stanley to Trade 2020 Election With ETFs
Morgan Stanley outlined four outcomes of the 2020 election and its strategies for investors on how to make the most of them.
- ETF Trends
The Unloved Biotechnology ETF Rally
Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector. In a weekly update on the flow of money in and out of stock funds, PiperJaffray analyst Christopher J. Raymond pointed out that investors pulled a net $99 million out of healthcare and biotech-related funds in the one-week period ended on Wednesday, Barron's reports. The latest redemptions seems surprising given the recent outperformance of the biotechnology sector.
- Zacks
Biotech ETFs in Focus on Impressive Q3 Earnings Results
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
- Zacks
Value Biotech ETFs & Stocks to Buy Now
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
- Zacks
Healthcare ETFs Win in October: Here's Why
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
- MarketWatch
How to invest in biotech stocks like a Nobel Prize winner
Investors can ‘coat-tail’ on cancer-therapy researcher James Allison, who won medicine’s top prize in 2018.
- Zacks
Navigating The Healthcare Industry: Science Fiction Turns to Reality
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
- Zacks
Biotech ETFs Surge on a Flurry of Positive News
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
- Benzinga
VC Money Is Flowing Into Biotechs
Venture capitalists are pouring cash into U.S. biotechs at a rate set to replicate 2018’s record deal count, according to PitchBook and the National Venture Capital Association’s third-quarter Venture Monitor report. In the first three quarters alone, VCs struck 609 biopharma deals — the majority of which were Series A or B — and contributed $11.5 billion in investments. Compared to the stretch between 2005 and 2011, VC investments more than tripled to strike $2.3 billion between 2012 and 2018. What Does The VC Landscape Look Like?
- Investopedia
Adding Biotech ETFs to Your Portfolio
Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they're worth considering.
- ETF Database
Sell on the Pop Prospects: September 18 Edition
Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to be in a downtrend based on the fact that its 50-day moving average is below its 200-day moving average, which are popular indicators for gauging long-term and medium-term trends, respectively. Second, each of these ETFs is also trading above its 20-day moving average, thereby offering a near-term 'sell on the pop' opportunity given the longer-term downtrend at hand. Note that this prospects list also features a liquidity screen by excluding ETFs with average trading volumes below the one million shares mark. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
- Benzinga
10 ETFs That Could Be Primed For A Short Squeeze
Traders are always on the lookout for the next short squeeze candidate. Short squeezes can send share prices skyrocketing in a matter of minutes and hours, and traders who are along for the ride can make ...
- Kiplinger
6 Best Health Care Funds for a Volatile Market
Let's face it: The stock market is infuriating. Valuations are high, global growth is slow, and President Donald Trump's trade war with China has brought elevated volatility to stocks. Meanwhile, bonds, the only sensible alternative, are at near-record high prices and thus offer puny yields.What's an investor to do? One partial remedy is to increase your investment in health care stocks.Health care, which comprises more than 15% of Standard & Poor's 500-stock index, is the only broad market sector that can hold its own in both bull and bear markets. Although, no question, its best performance relative to the overall stock market comes during selloffs. In 2018, for instance, while the S&P; 500 retreated by 4.6% on a total-return basis (price plus dividends), the health care sector gained 5.6%.Which would you rather have: a shiny new BMW or your health? To ask the question is to answer it. If you're really sick, you'll do whatever it takes to recover, no matter the cost. You'll skip the new car, if necessary. Demand for health care is virtually inelastic. What's more, as baby boomers age, they're requiring more medical care. Simultaneously, breakthrough advances in the treatments of diseases - often expensive treatment - continue at a rapid clip.Below are my six best health care funds, in no particular order. SEE ALSO: The 19 Best ETFs for a Prosperous 2019
- InvestorPlace
Hexo Stock Is Down — But Not Out
Hexo (NYSE:HEXO) stock is down 20% year-to-date. This is while the S&P 500 is up more than 10% and the SPDR S&P Biotech ETF (NYSEARCA:XBI) is flat. So clearly, investors have shied away from buying HEXO stock specifically.Source: Shutterstock This is not necessarily alarming because investors are already nervous from extraneous factors. Wall Street has good reason to be hesitant to buy even proven stocks right now with so much uncertainty is looming. So they are not rushing into risky ones either.During such uncertain times, stocks like HEXO, which are relatively frothy don't get bid up. If investors are nervous they usually prefer buying strong fundamentals not hopium. Since it sells at 270 time its sales, the Hexo stock price has a lot of forward potential baked into it -- even down here.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Trading HEXO StockSo, under such uncertain conditions, I would only trade HEXO from a tactical vantage point. And that's the opportunity we will study today.HEXO stock is down 50% since the end of April. Clearly the bears are in control of it, but there is hope for the bulls. Last week when it was under severe selling pressure, it held the July bottom. So as long as the HEXO bulls can maintain the higher-low trend, they will have an opportunity to regain control of the price action. This is also happening inside a pivotal zone and those are usually supportive.To do that, HEXO stock price needs to rise above $4.50. This is a moving target so I consider it more of a range rather than a hard line in the sand.If the buyers are able to do this then HEXO could run another $1 from there. This would almost be the halfback retracement of the whole correction from $8.20 per share. * 7 Deeply Discounted Energy Stocks to Buy Since I deem this opportunity as tactical, it also means that the trade should have tight stops. This would eliminate the temptation of turning a trade into an investment.However, if traders know the company and expect its fundamentals to eventually blossom then this same opportunity here would also be a good long-term entry point. But in either case and with so much uncertainty, it is best to do it in stages and not a full position all at one.There is a technical caution from the weekly chart. The HEXO stock price pattern is expanding and testing the lower ends of the range. If the trend line breaks then they could target $3 per share. While this is not the obvious scenario unfolding, it is one that exists.The bottom line is that Wall Street is on edge so they won't have a lot of appetite to buy iffy stocks. HEXO is one that would likely need the general market help to find footing and recover higher levels. If it does then I'd trail profits near $5.50 then again at $6.30 per share.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room for free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Deeply Discounted Energy Stocks to Buy * 7 Stocks to Buy In a Flat Market * 10 Stocks to Buy to Ride China's Emerging Wealth The post Hexo Stock Is Down -- But Not Out appeared first on InvestorPlace.
